BioNexus Net Current Asset Value from 2010 to 2026
| BGLC Stock | USD 2.14 0.11 5.42% |
Net Current Asset Value | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check BioNexus Gene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNexus Gene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 184.9 K, Interest Expense of 25.5 K or Other Operating Expenses of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 0.57. BioNexus financial statements analysis is a perfect complement when working with BioNexus Gene Valuation or Volatility modules.
BioNexus | Net Current Asset Value | Build AI portfolio with BioNexus Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:Check out the analysis of BioNexus Gene Correlation against competitors. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Specialty Chemicals sector continue expanding? Could BioNexus diversify its offerings? Factors like these will boost the valuation of BioNexus Gene. Projected growth potential of BioNexus fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BioNexus Gene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.95) | Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioNexus Gene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioNexus Gene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioNexus Gene's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.